ResMed | RMD

Stock Price
277.05
Daily Change
3.24 1.18%
Monthly
-1.22%
Yearly
13.23%
Q3 Forecast
274.75

Peers Price Chg Day Year Date
Ansell 34.57 0.09 0.26% 15.08% Sep/05
AtriCure 35.38 -0.28 -0.79% 34.83% Sep/05
Baxter International 24.42 0.84 3.56% -37.34% Sep/05
Cochlear 298.53 -0.25 -0.08% 3.39% Sep/05
Cooper Companies 68.09 0.09 0.13% -36.13% Sep/05
CSL 209.25 -1.60 -0.76% -31.17% Sep/05
Dexcom 80.51 -0.25 -0.31% 17.11% Sep/05
Edwards Lifesciences 80.94 -0.02 -0.02% 21.19% Sep/05
Fisher Paykel Healthcare 37.89 0.76 2.05% 1.31% Sep/05
Globus Medical 60.60 0.31 0.51% -13.42% Sep/05
Haemonetics 54.38 0.30 0.55% -25.75% Sep/05
Hologic 66.76 0.37 0.56% -18.16% Sep/05
Integra LifeSciences 15.99 0.34 2.17% -13.57% Sep/05
Idexx Laboratories 642.99 2.55 0.40% 36.13% Sep/05
Intuitive Surgical 466.86 12.34 2.72% -1.06% Sep/05
Masimo 147.19 4.18 2.92% 31.97% Sep/05
Medtronic 92.93 0.13 0.14% 3.32% Sep/05
Philips 23.80 0.02 0.08% -12.63% Sep/06
Insulet 348.43 1.96 0.57% 62.25% Sep/05
Ramsay Health Care 33.66 -0.45 -1.32% -15.51% Sep/05
ResMed 277.05 3.24 1.18% 13.23% Sep/05
Sonic Healthcare 22.94 -0.07 -0.30% -15.63% Sep/05
Sigma Healthcare 3.04 0.01 0.33% 139.37% Sep/05
Steris 245.30 1.91 0.78% 2.42% Sep/05
Teleflex 130.70 1.61 1.25% -46.61% Sep/05
Thermo Fisher Scientific 492.60 3.11 0.64% -19.59% Sep/05

Indexes Price Day Year Date
US400 3297 16.31 0.50% 12.16% Sep/05
US500 6481 -20.59 -0.32% 19.84% Sep/05

ResMed traded at $277.05 this Friday September 5th, increasing $3.24 or 1.18 percent since the previous trading session. Looking back, over the last four weeks, ResMed gained 1.22 percent. Over the last 12 months, its price rose by 13.23 percent. Looking ahead, we forecast ResMed to be priced at 274.75 by the end of this quarter and at 267.97 in one year, according to Trading Economics global macro models projections and analysts expectations.

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep apnea, chronic obstructive pulmonary disease (COPD), neuromuscular disease and other chronic diseases. The Company operates through two segments: Sleep and Respiratory Care segment, and the Software-as-a-Service (SaaS) segment. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions.